Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Biological Chemistry

Editor-in-Chief: Brüne, Bernhard

Editorial Board: Buchner, Johannes / Lei, Ming / Ludwig, Stephan / Sies, Helmut / Thomas, Douglas D. / Turk, Boris / Wittinghofer, Alfred

12 Issues per year

IMPACT FACTOR 2017: 3.022

CiteScore 2017: 2.81

SCImago Journal Rank (SJR) 2017: 1.562
Source Normalized Impact per Paper (SNIP) 2017: 0.705

See all formats and pricing
More options …
Volume 390, Issue 4


Amidinoanthracyclines – a new group of potential anti-hepatitis C virus compounds

Mariusz Krawczyk / Malgorzata Wasowska-Lukawska / Irena Oszczapowicz / Anna M. Boguszewska-Chachulska
  • 4Institute of Biochemistry and Biophysics PAS, Pawinskiego 5a, 02-106 Warsaw, Poland and Genomed Ltd. Poland, Chelmska 30/34, 00-725 Warsaw, Poland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2009-02-07 | DOI: https://doi.org/10.1515/BC.2009.040


Hepatitis C virus (HCV) infections represent one of the major and still unresolved health problems because current therapy is effective in only 50–80% of cases, depending on viral genotype. A large group of amidinoanthracyclines, with decreased acute toxicity and cardiotoxicity compared to the parent antibiotics, was tested in a high-throughput fluorometric HCV helicase assay. Here, we report the selection of more than 50 potent inhibitors of helicase activity that inhibit the enzyme with IC50 values in the range of 0.03–10 μm; four of these compounds are the most potent inhibitors of helicase activity described in the literature. The activity of these inhibitors is highly dependent on their chemical structure, mainly on the substituent at the amidino carbon atom and on the orientation of the hydroxyl group at the 4′ position of the daunosamine moiety. The most effective compounds act not solely via intercalation into the double-stranded DNA substrate, but also compete with the enzyme for access to the substrate, impeding formation of the active helicase complex. Selected amidinoanthracyclines were tested in the subgenomic HCV replicon system. These experiments confirmed the antiviral activity of two selected inhibitors (EC50 values below 0.2 μm with selectivity indices of 19 and 33) and proved that they may be considered as potential anti-HCV drugs.

Keywords: amidinoanthracyclines; anthracycline derivatives; anti-HCV; hepatitis C virus; NS3 helicase; subgenomic HCV replicon

About the article

Corresponding author

Received: 2008-08-26

Accepted: 2009-01-26

Published Online: 2009-02-07

Published in Print: 2009-04-01

Citation Information: Biological Chemistry, Volume 390, Issue 4, Pages 351–360, ISSN (Online) 1437-4315, ISSN (Print) 1431-6730, DOI: https://doi.org/10.1515/BC.2009.040.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Mariana Nogueira Batista, Paulo Ricardo da Silva Sanches, Bruno Moreira Carneiro, Ana Cláudia Silva Braga, Guilherme Rodrigues Fernandes Campos, Eduardo Maffud Cilli, and Paula Rahal
Scientific Reports, 2018, Volume 8, Number 1
Jacqueline Farinha Shimizu, Carina Machado Pereira, Cintia Bittar, Mariana Nogueira Batista, Guilherme Rodrigues Fernandes Campos, Suely da Silva, Adélia Cristina Oliveira Cintra, Carsten Zothner, Mark Harris, Suely Vilela Sampaio, Victor Hugo Aquino, Paula Rahal, Ana Carolina Gomes Jardim, and Jason Blackard
PLOS ONE, 2017, Volume 12, Number 11, Page e0187857
Guilherme Rodrigues Fernandes Campos, Cíntia Bittar, Ana Carolina Gomes Jardim, Jacqueline Farinha Shimizu, Mariana Nogueira Batista, Eder Ramos Paganini, Letícia Ribeiro de Assis, Christopher Bartlett, Mark Harris, Vanderlan da Silva Bolzani, Luis Octavio Regasini, and Paula Rahal
Journal of General Virology, 2017, Volume 98, Number 7, Page 1693
Kaneez Fatima, Shilu Mathew, Mohd Suhail, Ashraf Ali, Ghazi Damanhouri, Esam Azhar, Ishtiaq Qadri, and Shama Ahmad
PLoS ONE, 2014, Volume 9, Number 9, Page e106339
Atsushi Furuta, Masayoshi Tsubuki, Miduki Endoh, Tatsuki Miyamoto, Junichi Tanaka, Kazi Salam, Nobuyoshi Akimitsu, Hidenori Tani, Atsuya Yamashita, Kohji Moriishi, Masamichi Nakakoshi, Yuji Sekiguchi, Satoshi Tsuneda, and Naohiro Noda
International Journal of Molecular Sciences, 2015, Volume 16, Number 8, Page 18439
Sourav Mukherjee, Alicia M. Hanson, William R. Shadrick, Jean Ndjomou, Noreena L. Sweeney, John J. Hernandez, Diana Bartczak, Kelin Li, Kevin J. Frankowski, Julie A. Heck, Leggy A. Arnold, Frank J. Schoenen, and David N. Frick
Nucleic Acids Research, 2012, Volume 40, Number 17, Page 8607
Kelin Li, Kevin J. Frankowski, Craig A. Belon, Ben Neuenswander, Jean Ndjomou, Alicia M. Hanson, Matthew A. Shanahan, Frank J. Schoenen, Brian S. J. Blagg, Jeffrey Aubé, and David N. Frick
Journal of Medicinal Chemistry, 2012, Volume 55, Number 7, Page 3319
Irene Briguglio, Sandra Piras, Paola Corona, and Antonio Carta
International Journal of Medicinal Chemistry, 2011, Volume 2011, Page 1
Sandra Gemma, Stefania Butini, Giuseppe Campiani, Margherita Brindisi, Samantha Zanoli, Maria Pia Romano, Pierangela Tripaldi, Luisa Savini, Isabella Fiorini, Giuseppe Borrelli, Ettore Novellino, and Giovanni Maga
Bioorganic & Medicinal Chemistry Letters, 2011, Volume 21, Number 9, Page 2776
Andżelika Najda-Bernatowicz, Mariusz Krawczyk, Anna Stankiewicz-Drogoń, Maria Bretner, and Anna M. Boguszewska-Chachulska
Bioorganic & Medicinal Chemistry, 2010, Volume 18, Number 14, Page 5129
Stanley M. Lemon, Jane A. McKeating, Thomas Pietschmann, David N. Frick, Jeffrey S. Glenn, Timothy L. Tellinghuisen, Julian Symons, and Phillip A. Furman
Antiviral Research, 2010, Volume 86, Number 1, Page 79

Comments (0)

Please log in or register to comment.
Log in